Found: 14
Select item for more details and to access through your institution.
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 2, p. 488, doi. 10.1007/s10637-020-01017-x
- By:
- Publication type:
- Article
Insulin Secretagogues from Moringa oleifera with Cyclooxygenase Enzyme and Lipid Peroxidation Inhibitory Activities.
- Published in:
- Helvetica Chimica Acta, 2004, v. 87, n. 2, p. 317
- By:
- Publication type:
- Article
Chemical and Cytotoxic Constituents from the Stem of Machilus zuihoensis.
- Published in:
- Helvetica Chimica Acta, 2002, v. 85, n. 7, p. 1909, doi. 10.1002/1522-2675(200207)85:7<1909::AID-HLCA1909>3.0.CO;2-1
- By:
- Publication type:
- Article
Identification of metabolites in Withania sominfera fruits by liquid chromatography and high-resolution mass spectrometry.
- Published in:
- Rapid Communications in Mass Spectrometry: RCM, 2012, v. 26, n. 11, p. 1277, doi. 10.1002/rcm.6221
- By:
- Publication type:
- Article
Blood-Brain Barrier Permeability of Bioactive Withanamides Present in Withania somnifera Fruit Extract.
- Published in:
- Phytotherapy Research, 2014, v. 28, n. 8, p. 1260, doi. 10.1002/ptr.5118
- By:
- Publication type:
- Article
Glycyrrhiza uralensis Flavonoids Present in Anti-Asthma Formula, ASHMI<sup>TM</sup>, Inhibit Memory Th2 Responses in Vitro and in Vivo.
- Published in:
- Phytotherapy Research, 2013, v. 27, n. 9, p. 1381, doi. 10.1002/ptr.4862
- By:
- Publication type:
- Article
Withanamides in Withania somnifera fruit protect PC-12 cells from β-amyloid responsible for Alzheimer's disease.
- Published in:
- Phytotherapy Research, 2010, v. 24, n. 6, p. 859, doi. 10.1002/ptr.3033
- By:
- Publication type:
- Article
Blood-Brain Barrier Permeability of Bioactive Withanamides Present in Withania somnifera Fruit Extract.
- Published in:
- 2008
- By:
- Publication type:
- Journal Article
A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 1, p. 34, doi. 10.1002/cpt.3256
- By:
- Publication type:
- Article
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 770, doi. 10.1002/cpt.2503
- By:
- Publication type:
- Article
PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 6, p. 577, doi. 10.1002/psp4.12619
- By:
- Publication type:
- Article
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 7, p. 1131, doi. 10.1038/s41416-023-02436-2
- By:
- Publication type:
- Article
Asia‐inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 10, p. 1, doi. 10.1111/cts.70050
- By:
- Publication type:
- Article
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 9, p. 2075, doi. 10.1111/cts.13357
- By:
- Publication type:
- Article